Mithu Maheswaranathan, MD
Dr. Mithu Maheswaranathan is a rheumatologist at Duke University School of Medicine. He has an interest in digital medical education and health literacy. He is the creator of “Rheum OnePagers,” infographics to explain and simplify rheumatology. He also has a special interest in systemic lupus erythematosus (lupus) and is involved in clinical and collaborative research efforts as part of the Duke Lupus Clinic.
Articles by Mithu Maheswaranathan, MD
A study investigate physical activity characteristics in the non-pharmacologic management of lupus.
Dr. Mithu Maheswaranathan talks about the findings of a study which assessed obinutuzumab for patients with active lupus.
A recent study sought to better understand the clinical presentation, and prognosis of IgG4-related pachymeningitis.
Researchers sought to better address the gap in knowledge on acetaminophen safety in patients with osteoarthritis.
Dr. Mithu Maheswaranathan discusses the link between vitamin D levels and pregnancy outcomes in women with lupus.
A study sought to understand the use of herbal supplement treatment in adult patients with autoimmune skin diseases.
A study examined the phenotypic differences in patients with IgG4-RD with and without hypocomplementemia.
The role of dietary and lifestyle interventions in the management of rheumatic disease is poorly understood.
Dr. Mithu Maheswaranathan on a study that shows metformin is a promising complementary therapy for SLE.
A study assessed glucocorticoid regimens on renal response, infections, and mortality in patients with lupus nephritis.
There is increasing interest in the use of musculoskeletal ultrasound in pediatric rheumatology.
A study analyzed the use of after-visit instructions at rheumatology clinics.
A case series presented data on the efficacy of CAR T-cell treatment in patients with rheumatic autoimmune disease.
It is critical for physicians to be confident and comfortable in diagnosing and managing knee osteoarthritis.
Mithu Maheswaranathan, MD, spoke about challenges, treatments, and trends in rheumatology, as well as upcoming advancements.
A study aimed to create a benefit-versus-harm shared decision-making tool for hydroxychloroquine for patients with SLE.
A study provided a unique characterization of a rare: large-vessel involvement from ANCA-associated vasculitis.
A study sought to identify variables distinguishing inflammatory from noninflammatory arthritis in a large cohort.
Ultra-low dose rituximab significantly reduced the rate of infections versus the standard low dosage in rheumatoid arthritis.
Researchers examined changes in objective measures of cardiorespiratory function and patient-reported outcomes in lupus.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.